More about
Lapatinib
News
January 16, 2025
3 min read
Save
Adjuvant regimen extends survival in early HER2-positive breast cancer
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with HER2-positive breast cancer, according to long-term results of a randomized phase 3 trial.
News
December 17, 2020
6 min watch
Save
VIDEO: ‘Real world’ data for patients with HER2-positive, BRCA1/2 breast cancer
In this video, Elias Obeid, MD, MPH, discussed treatment patterns and clinical outcomes of patients with germline BRCA1/2-mutated, HER2-positive advanced breast cancer.